Cinacalcet - NDSRI's
References
FAQ's
References
- Van Wagenen, Bradford C.; Moe, Scott T.; Balandrin, Manuel F.; Delmar, Eric G.; Nemeth, Edward F., Calcium receptor-active compounds, NPS Pharmaceuticals, Inc., United States, US6211244B1, April 3, 2001
- Ravinder, Vadde; Ashok, Sigala; Varma, M. Satish; Babu, C. V. Raghunath; Shanker, Kanne; Balaswamy, Gubba, A validated chiral LC method for the enantiomeric separation of cinacalcet hydrochloride, Chromatographia, Volume: 70, Issue: ½, Pages: 229-232, 2009
Frequently Asked Questions
How does impurity analysis contribute to the quality assurance of Cinacalcet?
Impurity analysis ensures that Cinacalcet meets quality standards, regulatory requirements, and patient safety expectations, enhancing its quality assurance.
Are impurity profiles different among different brands of Cinacalcet?
The impurity profiles may vary among different brands of Cinacalcet due to variations in manufacturing processes, starting materials, or formulation techniques.
Which solvent helps in the analysis of Cinacalcet impurities?
Methanol is a solvent used in analyzing many impurities in Cinacalcet.
What are the temperature conditions required to store Cinacalcet impurities?
Cinacalcet impurities are stored at a controlled room temperature between 2-8 °C or as indicated on the Certificate of Analysis (CoA).
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.